<DOC>
	<DOCNO>NCT02541916</DOCNO>
	<brief_summary>The purpose study validate test tolerance gene expression profile identification operationally tolerant liver transplant recipient , allow successful withdrawal immunosuppression without rejection patient .</brief_summary>
	<brief_title>Liver Immune Tolerance Marker Utilization Study</brief_title>
	<detailed_description>Previous pre-clinical work Levy Lab identify novel biomarker gene set identification tolerance murine model rapamycin-induced cardiac tolerance spontaneous hepatic tolerance . Validation gene expression tolerance biomarker operationally tolerant patient require implementation clinical setting . This proposal intend validate test pre-clinically establish tolerance gene expression biomarker clinical set order translate finding improve length quality life transplant patient clinic . The investigator hypothesize distinct gene expression profile express peripheral blood identify operationally tolerant liver transplant recipient , allow successful withdrawal immunosuppression patient . Our study aim : ( I ) To validate pre-clinical gene expression profile identification operationally tolerant liver recipient plasma peripheral blood mononuclear cell ( PBMCs ) ( 2 ) To determine gene expression profile PBMCs intra-graft gene expression profile ( 3 ) To demonstrate liver transplant recipient tolerant gene expression profile safely wean immunosuppression . This proof principle study conduct two phase Toronto General Hospital ( TGH ) Phase 1 address study aim 1 2 , phase 2 address study aim 3 . Potential participant screen select follow predefined eligibility criterion . Eligible participant undergo informed consent process . The primary goal study validate pre-clinical tolerant gene expression profile allow identification tolerant liver recipient monitor wean immunosuppression tolerant patient .</detailed_description>
	<criteria>To eligible participate study , patient must : 1 . Be 18 65 year age . 2 . Be recipient hepatic allograft . 3 . Be less 3 month posttransplant experience rejection , minimum 3 month posttransplant without presently experience rejection . 4 . Be healthy live liver donor Patients follow condition may participate study : 1 . Patients age 18 age 65 . 2 . Patients positive Human Immunodeficiency Virus ( HIV ) , 3 . Patients detectable level HCV RNA , HBV DNA , time enrollment . 4 . Patients combine transplant and/or retransplanted . 5 . Patients take immunosuppression disease besides liver transplant . 6 . Patients unable give write informed consent accordance research ethic board guideline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Transplantation Tolerance</keyword>
	<keyword>Immune Tolerance</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Liver Transplantation</keyword>
	<keyword>Biological Markers</keyword>
	<keyword>Gene Expression</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Immunology</keyword>
	<keyword>Multiplex Polymerase Chain Reaction</keyword>
	<keyword>Real-Time Polymerase Chain Reaction</keyword>
</DOC>